N/A N=8 IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD
GVHD · Ocular Rosacea · Dry Eye Syndrome
Primary: Number of Participants Who Responded to Intense Pulsed Light (IPL) — 5; 2 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=70 Treatment of Patients With Blepharitis and Facial Rosacea
Blepharitis · Meibomianitis · Dry Eye
Primary: Change in Bulbar Conjunctival Hyperemia — -0.61; -0.60 Scores on a scale — p=0.578
Phase 2 N=24 Therapeutic Effects of Topical Herbal Medicine -Rhubarb Ointment on Rosacea
Rosacea · Chinese Herbal Medicine
Primary: Reduction of Flushing, Erythema, Telangiectasia, Papules, and Pustules — 1; 1.92 score on a scale
Phase 2 N=10 Open Label Pilot Study of Apremilast in Treatment of Rosacea
Erythematotelangiectatic Rosacea · Papulopustular Rosacea
Primary: Change From Baseline in the Total Number of Papulopustular Lesions at Week 12 — -0.2 papule count — p=0.98
Phase 4 N=46 Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea
Rosacea
Primary: Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) — 5; 0 Participants
N/A N=20 Efficacy of IPL Treatment of Dry Eye and Ocular Rosacea
Ocular Rosacea · Dry Eye
Primary: Change in Ocular Surface Disease Index (OSDI) Symptom Survey Score — -25.9; -2.0 percentage of change in OSDI score — p=0.0312
Phase 4 N=30 Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride (HCL) 1% Cream for Erythematotelangiectatic Rosacea
Erythematotelangiectatic Rosacea
Primary: Clinical Erythema Assessment (CEA) Score At 6-Month Post-Baseline — 1.6; 2.4 score on a scale
Phase 4 N=24 Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea
Papulopustular Rosacea
Primary: Rosacea Score on the Visual Analog Scale — 4.50; 4.52; 3.77; 3.06 units on a scale
Phase 4 N=30 Photodynamic Therapy for Papulopustular Rosacea
Rosacea · Papulopustular Rosacea
Primary: Improvement of the Inflammatory Lesions (Papules, Pustules, Nodules), Erythema, and Telangiectasia of Rosacea as Assessed by the Investigator's Global Assessment (IGA)…
Phase 4 N=273 Oracea Soolantra Association in Participants With Severe Rosacea
Rosacea
Primary: Percent Change From Baseline in Inflammatory Lesion Count at Week 12 — -80.29; -73.56 percent change — p=0.032
Phase 4 N=1,421 ORCA - Oracea® for Rosacea: A Community-based Assessment
Rosacea
Primary: Change in Investigator's Global Assessment (IGA) Score From Baseline to Endpoint — 0; 0; 0; 0 participants
Phase 2 N=30 Rosacea and Ivermectin
Rosacea
Primary: Adherence - MEMs Cap — 21; 6; 15; 12 Participants
Phase 2 N=10 An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema
Papulopustular Rosacea
Primary: Facial Erythema — 6.6; 6 score on a scale
Phase 2 N=100 Oral Azithromycin Versus Doxycycline in Posterior Blepharitis
Posterior Blepharitis
Primary: Change of Blepharitis Symptoms Score — 1.8; 2.8 score — p=0.03
Phase 3 N=440 A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Erythema Associated With Rosacea
Erythema · Rosacea
Primary: Percentage of Participants With Treatment-Related Adverse Events — 8.2 percentage of participants
Phase 2 N=24 Effects of PRK 124 Lotion in Acne Rosacea
Acne Rosacea
Primary: Erythema Severity — 44.53 Erythema percent improvement
Phase 4 N=170 Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo
Rosacea
Primary: Change From Baseline in Inflammatory Lesion Counts — -4.3; -3.2 inflammatory lesions
Phase 2 N=216 Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea
Papulopustular Rosacea
Primary: Co-primary Endpoint: Change From Baseline in Number of Rosacea Inflammatory Lesions — -10.0; -6.7; -9.2 lesions (rosacea inflammatory)
Phase 3 N=445 Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea
Erythema · Rosacea
Primary: Percentage of Participants With at Least a 2-Grade Improvement (Decrease) From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Self-Assessment for…
N/A N=22 Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea
Erythematotelangiectatic Rosacea · Papulopustular Rosacea
Primary: Degree of Improvement in Erythematotelangiectatic Rosacea and Papulopustular Rosacea — 2.114; 2.088 score on a scale
Phase 3 N=688 Phase 3 Papulopustular Rosacea Study
Papulopustular Rosacea
Primary: Success Rate — 40.1; 18.8 Percentage of participants — p=<0.001
Phase 3 N=683 Phase 3 Papulopustular Rosacea Study
Papulopustular Rosacea (PPR)
Primary: Success Rate — 38.4; 11.6 Percentage of participants — p=<0.001
Phase 3 N=449 Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
Rosacea
Primary: Long Term Safety & Efficacy of CD07805/47 Gel 0.5% in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea. — -1.5; -1.4; -1.5; -1.7 scores on a scale
N/A N=10 Combination Gel and Vascular ND in Mild to Moderate Rosacea
Rosacea
Primary: IGA of Improvement — 3.1; 3.5 units on a scale
Phase 4 N=106 Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues
Open Angle Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Mean Conjunctival Hyperemia Scores at Month 3 — 0.74; 0.86; 0.74; 0.05 Scores on Scale
Phase 3 N=50 An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea
Rosacea · Erythema
Primary: Responder — 16.7 percentage of responders
Phase 3 N=552 Comparative Safety and Efficacy of Two Rosacea Products in the Treatment of Facial Erythema of Rosacea
Rosacea
Primary: Proportion of Subjects With Composite Success — 60; 58; 23 Participants
Phase 2 N=61 A Study to Assess the Efficacy, Safety and Tolerability of DFD-04
Rosacea
Primary: Change in Inflammatory Lesion Counts — -1.4; 2.9 Number of lesions
Phase 3 N=20 Azelaic Acid on Demodex Counts in Rosacea
Rosacea
Primary: Demodex Count — 40; 18 number of demodex
Phase 2 N=140 A Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Rosacea
Rosacea
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 5; 6 Participants